Department of Pharmaceutical Sciences, University of Milan, Milan, Italy.
Department of Health Sciences, University of Milan, Milan, Italy.
Methods Mol Biol. 2022;2418:153-172. doi: 10.1007/978-1-0716-1920-9_10.
In spite of the fact that women spend 1/3 of their lives in postmenopause, the search for appropriate therapies able to counteract the derangements associated with the menopause still represents a sort of sought after the "Holy Grail."Nowadays, the combination of estrogens and selective estrogen receptor modulators (SERMs), a class of compounds with a mixed agonist/antagonistic activity on the estrogen receptor (ER) in various tissues, represents the most promising approach to improve postmenopausal women's health, by preserving the benefits while avoiding the side effects of estrogen-based therapy.Given their complex mechanisms of action, the evaluation of SERM activity in combination with conjugated estrogens (CE) requires a multifactorial analysis that takes into account the multifaceted and dynamic effects of these compounds in target tissues, even in relation to the physiological/pathological status.To accomplish such a goal, we took advantage of the ERE-Luc model, a reporter mouse that allows the monitoring of ER transcriptional activity in a spatio-temporal dimension. Cluster analyses performed on in vivo/ex vivo bioluminescence (BLI) data and ex vivo luciferase activity enabled to sustain the combination of CE plus bazedoxifene (TSEC, tissue-selective estrogen complex) as a valuable option for the pharmacological treatment of the postmenopause.
尽管女性有三分之一的时间处于绝经后,但寻找能够对抗与绝经相关的失调的合适疗法仍然是一种追求的“圣杯”。如今,雌激素和选择性雌激素受体调节剂(SERMs)的组合,一类在各种组织中对雌激素受体(ER)具有混合激动剂/拮抗剂活性的化合物,代表了改善绝经后妇女健康的最有前途的方法,通过保留益处,同时避免基于雌激素的治疗的副作用。鉴于其复杂的作用机制,SERMs 与结合雌激素(CE)联合活性的评估需要进行多因素分析,该分析考虑了这些化合物在靶组织中的多方面和动态作用,甚至与生理/病理状态有关。为了实现这一目标,我们利用了 ERE-Luc 模型,这是一种报告小鼠,允许在时空维度上监测 ER 转录活性。对体内/体外生物发光(BLI)数据和体外荧光素酶活性进行的聚类分析支持了 CE 加巴多昔芬(TSEC,组织选择性雌激素复合物)联合使用作为绝经后药物治疗的一种有价值的选择。